{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:24Z","timestamp":1791665964969,"version":"4.3.4"},"reference-count":27,"publisher":"The Endocrine Society","issue":"12","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Women's Board of Northwestern Memorial Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Systemic treatment of metastatic adrenocortical carcinoma (ACC) remains limited to chemotherapy and mitotane. Preliminary evidence suggesting that antitumor immune responses can be elicited in ACC has fostered interest in checkpoint inhibitors such as anti\u2013PD-1 nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The primary endpoint was objective response rate according to the response evaluation criteria in solid tumors. Secondary endpoints were progression-free survival (PFS), overall survival, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Single-arm, multicenter, phase 2 clinical trial with two-stage design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Comprehensive cancer center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Ten adult patients with metastatic ACC previously treated with platinum-based chemotherapy and\/or mitotane as well as patients who declined front-line chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Nivolumab (240 mg) IV every 2 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten patients with metastatic ACC were enrolled between March and December 2016. The median number of doses of nivolumab administered was two. Three patients only received one treatment [one died of disease progression, one discontinued due to adverse events (AEs), one withdrew after beginning treatment]. The median PFS was 1.8 months. The median follow-up was 4.5 months (range, 0.1 to 25.6 months). Two patients had stable disease for a duration of 48 and 11 weeks, respectively. One patient had an unconfirmed partial response but discontinued the study due to an AE. Most AEs were grade 1\/2. The most common grade 3\/4 treatment-related AEs were aspartate aminotransferase and alanine aminotransferase elevations, mucositis, and odynophagia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nivolumab demonstrated modest antitumor activity in patients with advanced ACC. The nivolumab safety profile was consistent with previous clinical experience without any unexpected AEs in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2019-00600","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T09:03:01Z","timestamp":1562317381000},"page":"6193-6200","source":"Crossref","is-referenced-by-count":110,"title":["Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-1126","authenticated-orcid":false,"given":"Benedito A","family":"Carneiro","sequence":"first","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Konda","sequence":"additional","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens B","family":"Costa","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo L B","family":"Costa","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Sagar","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"},{"name":"Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demirkan B","family":"Gursel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kwang","family":"Chae","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarki A","family":"Abdulkadir","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"},{"name":"Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Rademaker","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devalingam","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha H","family":"Shah","sequence":"additional","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J","family":"Giles","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"issue":"11","key":"2019103111293330600_bib1","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N","article-title":"Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature","volume":"72","author":"Wooten","year":"1993","journal-title":"Cancer"},{"issue":"6","key":"2019103111293330600_bib2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1210\/jc.2008-2291","article-title":"Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review","volume":"94","author":"Golden","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2019103111293330600_bib3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1210\/js.2018-00197","article-title":"Therapeutic targets for adrenocortical carcinoma in the genomics era","volume":"2","author":"Mohan","year":"2018","journal-title":"J Endocr Soc"},{"issue":"2","key":"2019103111293330600_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"5","key":"2019103111293330600_bib5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma [published correction appears in","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"issue":"23","key":"2019103111293330600_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2019103111293330600_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019103111293330600_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019103111293330600_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2019103111293330600_bib10","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019103111293330600_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-013-9878-1","article-title":"Everolimus therapy for progressive adrenocortical cancer","volume":"44","author":"Fraenkel","year":"2013","journal-title":"Endocrine"},{"issue":"4","key":"2019103111293330600_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial [published correction appears in Horm Cancer. 2014;5(6):424]","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Cancer"},{"issue":"4","key":"2019103111293330600_bib13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"2019103111293330600_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2004-814571","article-title":"Cytotoxic T-cell response against steroidogenic acute regulatory protein using DNA vaccination followed by vaccinia virus infection in a mouse adrenal carcinoma model","volume":"36","author":"Reincke","year":"2004","journal-title":"Horm Metab Res"},{"issue":"4","key":"2019103111293330600_bib15","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1210\/en.2003-0983","article-title":"Steroidogenic acute regulatory (StAR)-directed immunotherapy protects against tumor growth of StAR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model","volume":"145","author":"Ortmann","year":"2004","journal-title":"Endocrinology"},{"issue":"2","key":"2019103111293330600_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2265.2006.02576.x","article-title":"Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma","volume":"65","author":"Papewalis","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019103111293330600_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"3","key":"2019103111293330600_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/00401706.1984.10487964","article-title":"Confidence bands for survival functions with censored data: a comparative study","volume":"26","author":"Nair","year":"1984","journal-title":"Technometrics"},{"issue":"5","key":"2019103111293330600_bib19","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"issue":"19","key":"2019103111293330600_bib20","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2019103111293330600_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(17)30181-X","article-title":"Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial","volume":"18","author":"Kudo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019103111293330600_bib22","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"2019103111293330600_bib23","first-page":"793","article-title":"Hepatotoxicity of a synthetic cortisol antagonist: OP\u2019DDD (mitotane) [in French]","volume":"56","author":"Neuman","year":"2001","journal-title":"Therapie"},{"issue":"1","key":"2019103111293330600_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2019103111293330600_bib25","first-page":"87","article-title":"Efficacy of pembrolizumab (MK\u20103475) in patients with adrenocortical carcinoma","volume":"5","author":"Habra","year":"2017","journal-title":"J Immnother Cancer"},{"key":"2019103111293330600_bib26","first-page":"207","article-title":"The ENSAT registry: a digital repository supporting adrenal cancer research","volume":"178","author":"Stell","year":"2012","journal-title":"Stud Health Technol Inform"},{"issue":"5","key":"2019103111293330600_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40618-017-0775-y","article-title":"Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis","volume":"41","author":"Armignacco","year":"2018","journal-title":"J Endocrinol Invest"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-00600\/28903645\/jc.2019-00600.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/12\/6193\/30337911\/jc.2019-00600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/12\/6193\/30337911\/jc.2019-00600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T11:41:41Z","timestamp":1572522101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/12\/6193\/5528226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-00600","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,7,5]]}}}